Search
Pfizer Inc
PFEAdd to Watchlist
26.180USD
+0.040+0.15%
Close 05/29, 16:00（ET）Quotes delayed by 15 min
149.21BMarket Cap
19.88P/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
+0.15%
5 Days
+1.08%
1 Month
-0.30%
6 Months
+1.71%
Year to Date
+5.14%
1 Year
+11.64%
TradingKey Stock Score of Pfizer Inc
Currency: USD Updated: 2026-05-29Key Insights
Pfizer Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 56 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 29.06.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Pfizer Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Pfizer Inc Highlights
StrengthsRisks
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 62.58B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 119.41%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 119.41%.
Overvalued
The company’s latest PE is 19.88, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.98B shares, increasing 0.73% quarter-over-quarter.
Held by Murray Stahl
Star Investor Murray Stahl holds 68.95K shares of this stock.
Analyst Rating
Based on
32
analysts
Hold
Current Rating
29.062
Target Price
+11.18%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Pfizer Inc News
China Adds Eli Lilly and Pfizer to Its First Private Insurance List — Is This a Buying Opportunity for Biotech Investors?
TradingKey - China officially unveiled its first list of innovative drugs covered by commercial health insurance on December 7, greenlighting 19 high-priced therapies previously excluded from the National Reimbursement Drug List (NRDL).
TradingKeyMon, Dec 8
The Strategic Repositioning Driving Pfizer's Growth Story
TradingKey - Pfizer’s non-COVID portfolio grew 12% in 2024, led by a 65% surge in Vyndaqel sales and 26% oncology revenue growth.
TradingKeyApr 8, 2025
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Pfizer Inc Info
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Ticker SymbolPFE
CompanyPfizer Inc
CEOBourla (Albert)
Websitehttps://www.pfizer.com/
Related Instruments
-1.93%
-2.37%
-0.42%
-0.81%
-0.98%
+0.18%
+0.09%
-1.31%
+0.15%
+0.47%
-0.10%
-1.40%
-1.37%
-1.92%
0.00%
-1.08%
-0.30%
-1.18%
-1.53%Popular Instruments
86.839
-0.779 (-0.89%)
312.060
-0.450 (-0.14%)
211.140
-3.110 (-1.45%)
4537.420
+41.810 (+0.93%)
531.210
+0.030 (+0.01%)
1694.980
+53.340 (+3.25%)
971.000
+47.480 (+5.14%)
380.340
-9.790 (-2.51%)
73949.840
+306.230 (+0.42%)
435.790
-6.310 (-1.43%)
